BTG plc: Appointment of Non-executive Director
London, UK, 27 July 2016: BTG plc (LSE: BTG), the specialist healthcare company, today announces the appointment of Graham Hetherington as a non-executive director of the Board and Chair of the Audit Committee, effective from 1 August, 2016.
Graham has a broad range of international finance management and planning, audit, risk management and M&A experience. He was Chief Financial Officer of Shire plc from June 2008 to February 2014; Bacardi in 2007 and Allied Domecq plc from 1999 to 2005. He is a Fellow of the Chartered Institute of Management Accountants.
Garry Watts, BTG's Chairman, commented: "Graham brings a strong track record to BTG, with significant industry and finance experience which will be of great benefit to us as we continue to implement our growth plans. He will also help us to continue to strengthen our governance framework in his role as chair of the Audit Committee. He is replacing Giles Kerr (who will remain on the Board) in that role since Giles will have acted as chair for almost 9 years"
There are no further details to be disclosed in relation to paragraph 9.6.13R of the Financial Conduct Authority Listing Rules.
For further information please contact:
Andy Burrows, VP, Corporate & Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530605
Stuart Hunt, Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536
Ben Atwell/Simon Conway
+44 (0)20 3727 1000
BTG is an international specialist healthcare company that is developing and commercializing products targeting acute care, cancer and vascular diseases. The company has diversified revenues from sales of its own marketed products and from royalties on partnered products, and is seeking to acquire new programs and products to develop and market to specialist physicians.
For further information about BTG please visit our website at www.btgplc.com.